Страна: Індонезія
мова: індонезійська
Джерело: Badan Pengawas Obat dan Makanan RI - Indonesian Food and Drug Supervisory Agency
EZETIMIBE
ORGANON PHARMA INDONESIA TBK - Indonesia
EZETIMIBE
10 MG
TABLET
DUS, 3 BLISTER @ 10 TABLET
MSD INTERNATIONAL GMBH (PUERTO RICO BRANCH) LLC - Puerto Rico
2020-04-04
EZETROL Tablet Ezetimibe COMPOSITION Each tablet of EZETROL for oral administration contains 10 mg ezetimibe. THERAPEUTIC CLASS EZETROL is in a new class of lipid-lowering compounds that selectively inhibit the intestinal absorption of cholesterol and related plant sterols. MECHANISM OF ACTIONS Ezetimibe has a mechanism of action that differs from other classes of cholesterol- reducing compounds (e.g., statins, bile acid sequestrants [resins], fibric acid derivatives, and plant stanols). The molecular target of ezetimibe is the sterol transporter, Niemann-Pick C1-Like 1 (NPC1L1), which is responsible for the intestinal uptake of cholesterol and phytosterols. Ezetimibe localizes at the brush border of the small intestine and inhibits the absorption of cholesterol, leading to a decrease in the delivery of intestinal cholesterol to the liver. This causes a reduction of hepatic cholesterol stores and an increase in clearance of cholesterol from the blood. Ezetimibe does not increase bile acid excretion (like bile acid sequestrants) and does not inhibit cholesterol synthesis in the liver (like statins). In a 2- week clinical study in 18 hypercholesterolemic patients, EZETROL inhibited intestinal cholesterol absorption by 54 %, compared with placebo. By inhibiting the absorption of intestinal cholesterol, ezetimibe reduces the delivery of cholesterol to the liver. Statins reduce cholesterol synthesis in the liver. Together these distinct mechanisms provide complementary cholesterol reduction. EZETROL, administered with a statin, reduces total- C, LDL- C, Apo B, and TG and increases HDL- C in patients with hypercholesterolemia, beyond either treatment alone. Administration of EZETROL with fenofibrate is effective in improving serum total- C, LDL- C, Apo B, TG, HDL- C, DISETUJUI OLEH BPOM : 17/06/2021 ID : EREG100373VR12100073 and non- HDL- C in patients with mixed hyperlipidemia. The effects of Ezetimibe given either alone or in addition to an HMG-CoA reductase inhibitor or fenofibrate on cardiovascular morbidity an Прочитайте повний документ